Melanoma vs the double-edged sword | 47 min 1
Immune checkpoint inhibitors have revolutionised care for patients with advanced melanoma, with around half of patients with unresectable metastatic melanoma living to five years after treatment.
Over half of these patients who respond to immune checkpoint inhibitors will go on to survive long-term but it’s still not possible to identify responders in advance. On top of this, some of the immune-related side-effects of therapy can be serious enough to require stopping therapy.
In this interview from The Royal Australasian College of Physicians, MIA’s Medical Oncologist A/Prof Matteo Carlino explains how to approach the challenging conversations with patients about hopes around expectations for prognosis and quality of life.
The risk-benefit equation becomes harder to balance when considering treatment for grade III or even grade II melanomas, as an adjuvant to surgery. A/Prof Carlino also discusses the process of getting these new indications listed on the PBS, or how treatment can be funded when they are not.
This interview is from The Royal Australasian College of Physicians podcast series.
Please note that this podcast was accurate at the time of recording (March 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.
A/Prof Matteo Carlino
Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals
Clinical Associate Professor, The University of Sydney
Declaration of Interest
Mic Cavazzini DPhil
Podcast Program Manager, RACP